Top-News
Dienstag,
28.02.2017 22:25
von
PR Newswire
| Aufrufe: 40
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Mallinckrodt plc To Contact The Firm Before Lead Plaintiff Deadline
Flagge der World Health Organisation (WHO)
©United States Mission Geneva
https://www.flickr.com/people/41916075@N06
PR Newswire
NEW YORK, Feb. 28, 2017
NEW YORK, Feb. 28, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) of the March 27, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the District of Columbia on behalf of all those who purchased Mallinckrodt stock or options between November 25, 2014 and January 18, 2017 (the "Class Period"). The case, SHENK v. MALLINCKRODT PLC et al., No. 17-cv-00145 was filed on January 23, 2017.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the material adverse facts about the long-term sustainability of Mallinckrodt's monopolistic HP Acthar Gel ("Acthar") revenues and the exposure of Acthar to reimbursement rates by Medicare and Medicaid.
First, on November 16, 2016, Citron Research ("Citron") published a report accusing Chief Executive Officer ("CEO"), Mark Trudeau ("Trudeau"), and the Company of securities fraud in connection with Trudeau's statements downplaying the Company's reliance on Medicare and Medicaid for Acthar revenue. These accusations were supported by Trudeau's comments made during a Company conference call on November 29, 2016.
Then, on January 18, 2017, the Federal Trade Commission announced that Mallinckrodt had agreed to pay $100 million in connection with an investigation against the Company's anticompetitive and unlawful efforts to prevent an alternative ACTH treatment from reaching the U.S. market.
Request more information now by clicking here: www.faruqilaw.com/MNK. There is no cost or obligation to you.
Take Action
If you invested in Mallinckrodt stock or options between November 25, 2014 and January 18, 2017 and would like to discuss your legal rights, visit www.faruqilaw.com/MNK. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Mallinckrodt's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-mallinckrodt-plc-to-contact-the-firm-before-lead-plaintiff-deadline-300415192.html
SOURCE Faruqi & Faruqi, LLP
Werbung
Mehr Nachrichten zur Mallinckrodt Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
